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James Cotton, MD; Mitchell Lindsay, MD; Margaret McEntegart, PhD; J. Paul Rocchiccioli, MD; Richard Good, MD;  
Keith Robertson, PhD; Hany Eteiba, MD; Stuart Watkins, MD; Aadil Shaukat, MBChB; Colin J. Petrie, PhD;  
Aengus Murphy, MD; Mark C. Petrie, MBChB; Colin Berry , PhD
BACKGROUND: The resistive reserve ratio (RRR) expresses the ratio between basal and hyperemic microvascular resistance. 
RRR measures the vasodilatory capacity of the microcirculation. We compared RRR, index of microcirculatory resistance 
(IMR), and coronary flow reserve (CFR) for predicting microvascular obstruction (MVO), myocardial hemorrhage, infarct size, 
and clinical outcomes, after ST-segment–elevation myocardial infarction.
METHODS: In the T-TIME trial (Trial of Low-Dose Adjunctive Alteplase During Primary PCI), 440 patients with acute ST-
segment–elevation myocardial infarction from 11 UK hospitals were prospectively enrolled. In a subset of 144 patients, IMR, 
CFR, and RRR were measured post-primary percutaneous coronary intervention. MVO extent (% left ventricular mass) was 
determined by cardiovascular magnetic resonance imaging at 2 to 7 days. Infarct size was determined at 3 months. One-year 
major adverse cardiac events, heart failure hospitalizations, and all-cause death/heart failure hospitalizations were assessed.
RESULTS: In these 144 patients (mean age, 59±11 years, 80% male), median IMR was 29.5 (interquartile range: 17.0–55.0), CFR 
was 1.4 (1.1–2.0), and RRR was 1.7 (1.3–2.3). MVO occurred in 41% of patients. IMR>40 was multivariably associated with 
more MVO (coefficient, 0.53 [95% CI, 0.05–1.02]; P=0.031), myocardial hemorrhage presence (odds ratio [OR], 3.20 [95% CI, 
1.25–8.24]; P=0.016), and infarct size (coefficient, 5.05 [95% CI, 0.84–9.26]; P=0.019), independently of CFR≤2.0, RRR≤1.7, 
myocardial perfusion grade≤1, and Thrombolysis in Myocardial Infarction frame count. RRR was multivariably associated with MVO 
extent (coefficient, −0.60 [95% CI, −0.97 to −0.23]; P=0.002), myocardial hemorrhage presence (OR, 0.34 [95% CI, 0.15–0.75]; 
P=0.008), and infarct size (coefficient, −3.41 [95% CI, −6.76 to −0.06]; P=0.046). IMR>40 was associated with heart failure 
hospitalization (OR, 5.34 [95% CI, 1.80–15.81] P=0.002), major adverse cardiac events (OR, 4.46 [95% CI, 1.70–11.70] P=0.002), 
and all-cause death/ heart failure hospitalization (OR, 4.08 [95% CI, 1.55–10.79] P=0.005). RRR was associated with heart failure 
hospitalization (OR, 0.44 [95% CI, 0.19–0.99] P=0.047). CFR was not associated with infarct characteristics or clinical outcomes.
CONCLUSIONS: In acute ST-segment–elevationl infarction, IMR and RRR, but not CFR, were associated with MVO, myocardial 
hemorrhage, infarct size, and clinical outcomes.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02257294.
VISUAL OVERVIEW: A visual overview is available for this article.
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Immediate coronary revascularization by primary per-cutaneous coronary intervention (PCI) is the standard of care for patients with ST-segment–elevation myo-
cardial infarction (STEMI).1 Despite routinely restoring 
epicardial coronary blood flow, about half of patients 
have impaired myocardial perfusion.2 Invasive measures 
of microvascular dysfunction in the culprit artery have 
potential to guide the selection of patients for adjunctive 
therapies during primary PCI.3
Microvascular damage can be quantified on cardio-
vascular magnetic resonance (CMR), where it is referred 
to as microvascular obstruction (MVO), and is prognos-
tically important.4 However, CMR is not feasible imme-
diately post-reperfusion. Invasive coronary physiology 
parameters provide an immediate assessment of post-
PCI microvascular function. Among these parameters, 
the index of microcirculatory resistance (IMR) has been 
validated in animals5,6 and in humans.7–10 Higher IMR val-
ues indicate greater degrees of microvascular dysfunc-
tion7,11 and an IMR>40 predicts worse clinical outcomes 
(death, hospitalization for heart failure, and MI).11,12
Coronary flow reserve (CFR) reflects epicardial and 
microcirculatory vasodilator capacity, as well as residual 
epicardial stenosis. In acute STEMI, a lower CFR pre-
dicts MVO and larger infarction.7,13 However, compared 
with IMR>40, the combination of IMR>40 and CFR≤2.0 
did not have incremental prognostic value.12
The resistive reserve ratio (RRR)14–16 is a newer, 
less well-studied parameter. RRR is derived as the ratio 
between basal resting tone in the microcirculation and 
microcirculatory resistance at maximal hyperemia.14 RRR 
describes the ability of the coronary microcirculation to 
vary its resistance in response to a hyperemic stimulus, 
for example, adenosine.14 Higher RRR values indicate 
greater vasodilatation of the microcirculation in response 
to hyperemia, while lower RRR values indicate poor vaso-
dilator capacity of the coronary microcirculation. RRR is 
a measure of the microvascular vasodilatory response, 
which integrates measurement of pressure (microvascu-
lar resistance), thereby RRR is theoretically distinct from 
CFR. In contrast, IMR does not reflect microvascular 
vasodilator capacity. Whether these differences may be 
clinically significant is uncertain.
We predefined this physiology substudy of the T-TIME 
trial (Trial of Low-Dose Adjunctive Alteplase During Pri-
mary PCI). The principle aim was to compare the associa-
tions of IMR, CFR, and RRR with MVO extent (a reference 
surrogate outcome measure of failed microvascular 
reperfusion). Second, we compared the associations of 
IMR, CFR, and RRR with myocardial hemorrhage, infarct 
size, and clinical outcomes. We hypothesized that IMR, 
CFR, and RRR would be associated with infarct char-
acteristics and clinical outcomes, and that RRR would 
more closely associate with microvascular dysfunction 
than CFR.
METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
The patients were enrolled into the prespecified physiol-
ogy substudy of the T-TIME trial,17 which was a double-blind 
Nonstandard Abbreviations and Acronyms
AUC area under the curve
CFR coronary flow reserve
CMR cardiovascular magnetic resonance
IMR index of microcirculatory resistance
MACE major adverse cardiac events
MPG myocardial perfusion grade
MVO microvascular obstruction
NRI net reclassification improvement
OR odds ratio
PCI percutaneous coronary intervention
RRR resistive reserve ratio
STEMI  ST-segment–elevation myocardial 
infarction
TFC TIMI frame count
TIMI Thrombolysis in Myocardial Infarction
WHAT IS KNOWN
• Invasive physiology parameters that predict microvas-
cular obstruction and prognosis may become useful 
for selection of patients for adjunctive therapies dur-
ing primary percutaneous coronary intervention.
• Resistive reserve ratio is a measure of the vasodila-
tor capacity of the microcirculation, whereas index 
of microcirculatory resistance is a measure of the 
minimum achievable microvascular resistance at 
peak hyperemia.
• There is a lack of data on the comparative signifi-
cance of established and novel invasive measures 
of coronary vascular function, for predicting micro-
vascular injury and prognosis, in patients with acute 
ST-segment–elevation myocardial infarction.
WHAT THE STUDY ADDS
• Index of microcirculatory resistance and resistive 
reserve ratio reflect different aspects of micro-
vascular function, are complementary and are 
associated with microvascular obstruction extent, 
myocardial hemorrhage presence, infarct size and 
clinical outcomes.
• Our findings support using the index of microcir-
culatory resistance in conjunction with resistive 
reserve ratio instead of coronary flow reserve, as a 
tool to select patients for adjunctive therapy during 
primary percutaneous coronary intervention.
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randomized clinical trial of adjunctive intracoronary alteplase 
(10 or 20 mg) versus placebo delivered post-reperfusion, but 
pre-stenting, and found no difference in MVO at 2 to 7 days. 
From 2016 to 2017, 144 patients with STEMI ≤6 hours from 
symptom onset, from 3 UK hospitals, were enrolled. Eligibility 
criteria (Data Supplement) included occlusion or reduced 
flow (Thrombolysis in Myocardial Infarction [TIMI] coronary 
flow grade ≤2) in the culprit artery, with thrombus evident 
angiographically. The study was approved by the National 
Research Ethics Service (13-WS-0119) and complied with the 
Declaration of Helsinki. Witnessed verbal assent to participate 
was obtained in the catheterization laboratory. Written informed 
consent was subsequently obtained on the ward.
Invasive Coronary Physiology
IMR, CFR, and RRR were measured at the end of primary PCI 
using a pressure- and temperature-sensing guidewire (Abbott, 
Vascular, CA). Intracoronary nitroglycerin (200 µg) was admin-
istered into the culprit artery. A calibrated wire was equalized 
to guide catheter pressure, then advanced to the distal third of 
the culprit artery. Using standard thermodilution methods, the 
mean transit time (Tmn) of a hand-injected 3 mL bolus of room 
temperature saline was measured in triplicate at rest and dur-
ing steady-state maximal hyperemia, induced by intravenous 
adenosine (140 µg/kg per minute). Simultaneous measure-
ments of Pa and Pd were made.
IMR was defined as Pd×Tmn during hyperemia.5 When IMR 
was measured after stenting, there was no residual epicar-
dial stenosis, and therefore IMR correction with wedge pres-
sure,18 or Yong’s formula19 was not required. A threshold of 40 
was used to dichotomize IMR in regression analyses because 
based on published literature an IMR>40 is prognostically sig-
nificant. CFR was quantified by dividing resting Tmn by hyper-
emic Tmn.20 A threshold of 2.0 was used to dichotomize CFR 
in regression analyses because based on published literature a 
CFR≤2.0 is considered abnormal.12
Baseline resistance index (BRI) is a measure of the resting 
tone in the coronary microcirculation and was calculated using 
the following previously validated equation14:
BRI  Pd x TmnBaseline Baseline=
To measure the ability of the coronary microcirculation to 
undergo vasodilatation in response to a pharmacological hyper-
emic stimulus, the RRR was calculated as previously described:
RRR  BRI IM R= /
RRR measures the ability of the coronary microcirculation to 
change from baseline to minimal resistance in response to 
adenosine, thereby RRR reflects the ability to achieve maximal 
hyperemia. There are no established cutoffs for RRR; therefore, 
RRR was dichotomized by the median value, which is the con-
ventional approach taken by previous studies.15
To mitigate potential bias through disclosure of coro-
nary physiology results, operators were blinded, by obscuring 
the display of the RadiAnalyzer Xpress monitor. Experienced 
physiology technicians recorded the thermodilution data and 
quality assured the acquisition. Data were extracted from 
the RadiAnalyzer Xpress instrument and analyzed offline 
(Coroventis Research AB, Uppsala, Sweden).
The coronary physiology parameters were calculated pro-
spectively and were submitted to the data coordination center 
before data lock. The coronary physiology analyses were per-
formed by an observer blinded to the CMR data, and vice versa.
Angiogram Analyses
Angiographic end points were determined by blinded core lab-
oratory analysis. Angiographic analyses included the following: 
TIMI coronary flow grade, corrected TIMI frame count (TFC), 
myocardial perfusion grade (MPG), and TIMI thrombus grade in 
the culprit artery (Methods in the Data Supplement).
Cardiovascular Magnetic Resonance
CMR imaging was performed at 1.5-Tesla. MVO was reported 
at 2 to 7 days. CMR was also performed at 3 months. The CMR 
protocol has previously been described in detail.7,12,17 MVO 
presence and extent, and infarct size, (% left ventricle mass) 
were demonstrated by late gadolinium enhancement images. 
Myocardial hemorrhage presence and extent (% left ventricle 
mass) was demonstrated by T2* mapping.
Clinical Outcomes
Information on serious adverse events during follow-up was 
obtained by site research staff. These events were reviewed 
and adjudicated by the clinical events committee, comprising 
of 3 cardiologists who were independent of the trial. Clinical 
events were assessed at 1 year.
We prespecified clinical outcomes that are pathophysiologi-
cally linked with the natural history of STEMI. The clinical out-
comes were the following: (1) heart failure hospitalization; (2) 
all-cause death and heart failure hospitalization; and (3) major 
adverse cardiac events (MACE), defined as cardiac death, non-
fatal MI, or hospitalization for heart failure. Clinical follow-up 
was completed for all subjects.
Hospitalization for heart failure was defined as the follow-
ing: (1) new or worsening signs/ symptoms of heart failure 
requiring the initiation of, or increase in heart failure directed 
treatment (including intravenous therapy), or occurring in a 
patient already receiving maximal heart failure therapy, or (2) 
confinement to bed predominantly due to heart failure symp-
toms, or (3) pulmonary edema sufficient to cause tachypnoea 
and distress (not occurring in the context of an acute MI, wors-
ening renal function [that is not wholly explained by worsen-
ing heart failure], or as the consequence of arrhythmia without 
worsening heart failure), or (4) cardiogenic shock.
Statistics
Continuous data were summarized using mean±SD, or median 
and interquartile ranges if skewed. Categorical variables were 
reported as frequency and percentages. The associations 
between coronary physiology parameters and MVO extent were 
assessed by linear regression and were adjusted for the fol-
lowing covariates: TFC post-PCI, MPG≤1 post-PCI and other 
coronary physiology parameters, that is, CFR dichotomized by 
2, RRR dichotomized by median, and IMR dichotomized by 40. 
There was a priori concern that these covariates were clinically 
relevant confounders. Continuous coronary physiology param-
eters were not included as covariates together in the same 
D
ow
nloaded from
 http://ahajournals.org by on June 8, 2020
Maznyczka et al Coronary Physiology Parameters in Acute MI
Circ Cardiovasc Interv. 2020;13:e008505. DOI: 10.1161/CIRCINTERVENTIONS.119.008505 May 2020 4
model, due to collinearity. The regression coefficients from lin-
ear regression represented mean change in the extent of the 
outcome for a 1-unit increase in the predictor. The validity of 
linear and logistic regressions was verified by analysis of model 
residuals, linearity condition, testing for heteroscedasticity, and 
multicollinearity. In linear regression models, square root trans-
formations were used where necessary to improve model resid-
ual distributions. The associations between IMR, RRR, or CFR 
with MVO and myocardial hemorrhage extent were assessed 
by Spearman rank correlation coefficients. Receiver operating 
characteristic curve analysis was performed to investigate the 
relationship between IMR, RRR, or CFR with MVO, and myo-
cardial hemorrhage presence/absence, and clinical outcomes. 
Optimal predictive thresholds were derived from receiver oper-
ating characteristic curves. In this, sensitivity and specificity 
were considered equally important; therefore, the optimal cutoff 
was considered as the one giving the maximum Youden index. 
Receiver operating characteristic comparisons were made using 
the DeLong method. The incremental predictive ability of RRR 
was evaluated by calculating the continuous net reclassification 
improvement (NRI). Associations with heart failure hospitaliza-
tions, death/heart failure hospitalizations, or MACE were also 
evaluated using odds ratios (ORs), derived from logistic regres-
sion. All tests were 2-tailed, and a P value of <0.05 was consid-
ered statistically significant. There was no imputation for missing 
values. Statistical analyses were performed in SPSS (version 
25.0, SPSS, IBM, Armonk, NY), MedCalc Statistical Software 
version 18 (MedCalc Software, Ostend, Belgium), or Rv3.2.4.
RESULTS
Study Population Characteristics
The sample size (n=144) represented 33% of the overall 
T-TIME population and their characteristics were broadly 
similar (mean age 59±11 years, 80% male [Table 1, 
Figure 1]).
Associations With Physiology Parameters
The characteristics that were associated with lower 
RRR, on multivariable linear regression, were: CFR≤2.0 
(P<0.001) and IMR>40 (P=0.034). The characteris-
tics that were associated with higher IMR were: higher 
TFC (P=0.015), MPG≤1 (P=0.017), and RRR≤1.7 
(P=0.004). The only characteristic that was associated 
with lower CFR, on multivariable linear regression analy-
sis, was RRR≤1.7 (P<0.001).
RRR was correlated with IMR (rho=−0.32; 
P=0.0001). RRR and CFR were correlated (rho=0.94, 
P<0.0001). CFR was correlated with IMR (rho=−0.30; 
P=0.0002) (Figure 2).
When CFR was dichotomized by 2, RRR by 1.7, 
and IMR by 40, discordance between CFR and RRR 
occurred in in 38 patients (26.4%), discordance 
between CFR and IMR occurred in 66 patients (45.9%), 
and discordance between RRR and IMR occurred in 50 
patients (34.7%) (Figure 2).
Associations of Physiology Parameters With 
CMR Characteristics
The CMR findings (Table I in the Data Supplement) reported 
below were broadly similar when the 18 patients with final 
TIMI coronary flow grades ≤2 were not included in the 
analyses (Tables II and III in the Data Supplement). Further-
more, the findings were broadly similar when RRR≤1.7 was 
substituted for RRR≤2.0 in multivariable regression analy-
ses (Tables IV through VI and Figure I in the Data Supple-
ment). Regression analyses using dichotomizations for 
IMR, CFR, and RRR according to optimal thresholds from 
the area under the curve (AUC) are also shown (Tables IV 
through VII in the Data Supplement).
Relationships of Physiology Parameters With 
MVO
MVO was evaluable in 140 patients (97%). Given the 
high proportion of patients with a value of 0 for MVO 
(n=83 [59%]), the median MVO extent was 0.0 (inter-
quartile range, 0.0–3.3). MVO was present in 57 patients 
(40.7%).
IMR
Higher IMR measured acutely correlated with more 
MVO (rho=0.20, P=0.016; Figure II in the Data Supple-
ment). IMR was >40 in 55 patients, of whom 32 (58.2%) 
had MVO present. The optimal IMR threshold from the 
AUC for predicting MVO presence was >40 (Figure 3). 
IMR>40 was multivariably associated with MVO extent 
and presence, independently of CFR≤2.0, RRR≤1.7, TFC, 
and MPG≤1, whereas continuous IMR was not (Table 2).
CFR
Lower CFR correlated with more MVO (rho=−0.27; 
P=0.001; Figure II in the Data Supplement). CFR was 
≤2.0 in 112 patients, of whom 47 (42.1%) had MVO 
present. The optimal CFR threshold from the AUC for 
predicting MVO presence was ≤1.2 (Figure 3). Neither 
continuous CFR, nor CFR≤2.0, were associated with 
MVO (Table 2).
RRR
Lower RRR was correlated with more MVO (rho=−0.33; 
P=0.001; Figure II in the Data Supplement). RRR was 
≤1.7 (median) in 75 patients, of whom 37 (49.3%) had 
MVO present. The optimal RRR threshold from the AUC 
for predicting MVO presence was ≤1.5 (Figure 3). Lower 
RRR was multivariably associated with MVO extent and 
presence, whereas RRR≤1.7 was associated with MVO 
extent, but not MVO presence (Table 2). The overall NRI, 
reflecting the incremental predictive accuracy for detect-
ing the presence of MVO, was 0.66 (95% CI, 0.36–0.95; 
P<0.001) when RRR was added to a baseline model 
incorporating CFR≤2.0. When RRR≤1.7 was added to 
the baseline model containing CFR≤2.0, the NRI for 
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detecting MVO presence was 0.34 (95% CI, 0.06–
0.61; P=0.018). When the baseline model incorporated 
IMR>40, the overall NRI for detecting the presence of 
MVO was 0.38 (95% CI, 0.05–0.70; P=0.025) when 
RRR≤1.7 was added and was 0.29 ([95% CI, −0.02 to 
0.59]; P=0.068) when RRR was added.
RRR and CFR in Combination
Compared with RRR>1.7 and CFR≤2.0 combined (refer-
ence group), the group with the combination of RRR≤1.7 
and CFR≤2.0 was associated with an increased odds of 
MVO presence (37/75 [49.3%] versus 10/37 [27.0%]; 
OR, 2.63 [95% CI, 1.12–6.18]; P=0.027), and with more 
MVO (0.0 [0.0–5.3] versus 0.0 [0.0–0.8]; coefficient, 
0.74; [95% CI, 0.22–1.25]; P=0.006).
Relationships of Physiology Parameters With 
Myocardial Hemorrhage
Myocardial hemorrhage (the secondary manifestation 
of persistent MVO) occurred in 56 (41.2%) patients. 
Among those patients in whom myocardial hemorrhage 
was present, the median IMR was 41.5 (19.0–59.0), 
CFR was 1.2 (1.1–1.8), and RRR was 1.5 (1.2–2.2). 
Using multivariable logistic regression, patient and pro-
cedure characteristics that remained associated with 
the presence of myocardial hemorrhage were IMR>40 
(P=0.034), MPG≤1 (P=0.006), and larger initial TIMI 
thrombus grade (P=0.033).
IMR
Myocardial hemorrhage occured in 31 (58.5%) patients 
with an IMR>40. The optimal IMR threshold for predicting 
myocardial hemorrhage presence was >40 (Figure 3). 
IMR>40 was multivariably associated with myocardial 
IMR>40 57 (39.6)
CFR 1.4 (1.1–2.0)
CFR≤2.0 115 (79.9)
RRR 1.7 (1.3–2.3)
RRR≤1.7 77 (53.6)
Hyperemic Tmn (s) 0.4 (0.3–0.8)
Data are median (IQR), mean±SD, or n (%). BMI indicates body mass index; 
CFR, coronary flow reserve; eGFR, estimated glomerular filtration rate; IMR, 
index of microcirculatory resistance; IQR, interquartile range; LAD, left anterior 
descending; MI, myocardial infarction; PCI, percutaneous coronary intervention; 
QCA, quantitative coronary angiography; RCA, right coronary artery; RRR, resis-
tive reserve ratio; TFC, TIMI frame count; TIMI, Thrombolysis in Myocardial Infarc-
tion; and Tmn, mean transit time.
*Diabetes mellitus was defined as a history of diet-controlled or treated dia-
betes mellitus.
†Missing data: eGFR,, 1 subject. None of the patients received intravenous, or 
intracoronary treatment with bivalirudin, metoprolol, nicorandil, or sodium nitro-
prusside.
‡A diseased vessel was defined as having >50% stenosis in a major coronary 
artery, by angiographic visual assessment.
Table 1. Continued
Characteristic N=144
Table 1. Population and Procedure Characteristics (n=144)
Characteristic N=144
Age, y 59.4±10.5
Sex, male 115 (79.9)
Current smoker 68 (47.2)
Diabetes mellitus* 16 (11.1)
Hypertension 41 (28.5)
BMI, kg/m2 28.1 (24.6-31.0)
Previous MI 8 (5.6)
Previous PCI 9 (6.3)
eGFR† 88.8 (75.8–102.7)
Ischemic time, h:mm 2:47 (2:03–3:50)
Culprit coronary artery
 LAD 54 (37.5)
 RCA 66 (45.8)
 Circumflex 24 (16.7)
Number of vessels diseased‡
 1 83 (57.6)
 2 49 (34.0)
 3 12 (8.3)
Initial TIMI thrombus grade
 3 3 (2.1)
 4 25 (17.4)
 5 116 (80.6)
Initial TIMI coronary flow grade in culprit artery
 0 114 (79.2)
 1 14 (9.7)
 2 16 (11.1)
TIMI coronary flow in culprit artery post-PCI
1 3 (2.1)
2 15 (10.4)
3 126 (87.5)
TFC in culprit artery post-PCI 18.0 (14.0–26.0)
Myocardial perfusion grade post-PCI
 0 42 (29.2)
 1 3 (2.1)
 2 60 (41.7)
 3 39 (27.1)
PCI with stent implantation 144 (100)
QCA reference vessel diameter post-PCI 3.2±0.4
QCA total stent length, mm 33.2 (26.1–45.8)
Aspirin loading dose
 300 mg 142 (98.6)
 None 2 (1.4)
Glycoprotein IIbIIIa inhibitor during PCI 8 (5.6)
Aspiration thrombectomy 23 (16.0)
Intracoronary alteplase during PCI
 10 mg 41 (28.5)
 20 mg 50 (34.7)
IMR 29.5 (17.0–55.0)
(Continued )
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Figure 1. Flow of subjects through the study.
CFR indicates coronary flow reserve; CMR, cardiovascular magnetic resonance; IMR, index of microcirculatory resistance; MVO, 
microvascular obstruction; PCI, percutaneous coronary intervention; RRR, resistive reserve ratio; and STEMI, ST-segment–
elevation myocardial infarction.
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hemorrhage extent and presence, whereas continuous 
IMR was not (Table 2).
CFR
Lower CFR correlated with more myocardial hemor-
rhage (rho=−0.23, P=0.008) (Figure II in the Data 
Supplement). Myocardial hemorrhage was present in 
46 (42.6%) patients with CFR≤2.0. The optimal CFR 
threshold for predicting myocardial hemorrhage pres-
ence was ≤1.2 (Figure 3). Neither continuous CFR, nor 
CFR≤2.0, were multivariable associates with myocardial 
hemorrhage (Table 2).
RRR
Lower RRR was correlated with more myocardial hem-
orrhage (rho=−0.28; P=0.001) (Figure II in the Data 
Supplement). Myocardial hemorrhage was present in 
36 (50.0%) patients with RRR≤1.7. The optimal RRR 
threshold for predicting myocardial hemorrhage pres-
ence from the AUC was ≤1.5 (Figure 3). Lower RRR 
was multivariably associated with myocardial hemor-
rhage extent and presence, whereas RRR≤1.7 was 
associated with myocardial hemorrhage extent, but not 
its presence (Table 2). The overall NRI, reflecting the 
incremental predictive accuracy for detecting the pres-
ence of myocardial hemorrhage was 0.62 (95% CI, 
0.32–0.91) P<0.001, when RRR was added to a base-
line model incorporating CFR≤2.0. When RRR≤1.7 
was added to the baseline model containing CFR≤2.0, 
the NRI for detecting myocardial hemorrhage pres-
ence was 0.34 ([95% CI, 0.05–0.62]; P=0.021). When 
the baseline model incorporated IMR>40, the overall 
NRI for detecting the presence of myocardial hemor-
rhage was 0.39 ([95% CI, 0.04–0.72]; P=0.026) when 
RRR≤1.7 was added, and was 0.25 ([95% CI, −0.07 to 
0.56]; P=0.131) when RRR was added.
CFR and RRR in Combination
Compared with CFR≤2.0 and RRR>1.7 combined (refer-
ence group), the group with the combination of CFR≤2.0 
and RRR≤1.7 was associated with an increased odds 
of myocardial hemorrhage presence (36/72 [50.0%] 
versus 10/36 [27.8%]; OR, 2.60; [95% CI, 1.10–6.17]; 
P=0.030), and with myocardial hemorrhage extent (0.0 
[0.0–4.6] versus 0.0 [0.0–0.2]; coefficient, 0.62 [95% CI, 
0.11–1.12]; P=0.017).
Relationships of Physiology Parameters With 
3-Month Infarct Size
Infarct size 3-month post-PCI was evaluable in 133 
patients. The mean infarct size was 17.0±11.5%. Higher 
IMR was correlated with larger infarct size (rho=0.41; 
P<0.001) and IMR>40 was a multivariable associate of 
larger infarct size (Table 3).
Lower CFR was correlated with larger infarct size 
(rho=−0.23; P=0.007), but there was no associa-
tion when assessed by multivariable linear regression 
(Table 3).
Figure 2. Scatterplots showing correlations between 
coronary physiology parameters.
The following correlations are shown: (A) coronary flow reserve 
(CFR) and resistive reserve ratio (RRR); (B) index of microcirculatory 
resistance (IMR) and CFR; and (C) RRR and IMR. Also shown is 
discordance between dichotomized coronary physiology parameters 
and presence/absence of microvascular obstruction.
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Lower RRR was correlated with infarct size 
(rho=−0.22; P=0.012) and multivariably associated with 
larger infarct size (Table 3).
Relationships of Physiology Parameters With 
Adjudicated Clinical Outcomes
At 1-year follow-up, there were 19 adjudicated hospi-
talizations for heart failure, 22 for all-cause death/heart 
failure hospitalization combined, and 23 MACE events.
IMR
In patients with IMR>40, heart failure hospitalizations 
occurred in 14 patients (24.6%) at 1 year, death/heart 
failure hospitalization occurred in 15 patients (26.3%), 
and MACE occurred in 16 (28.1%) patients. The optimal 
IMR threshold from the AUC for predicting heart failure 
hospitalization, or death/ heart failure hospitalization was 
>44 (AUCs: 0.75 [P<0.001] and 0.72 [P<0.001], respec-
tively). The optimal IMR threshold from the AUC for 
predicting MACE was also >44 (AUC: 0.73 [P<0.001]; 
Figure 3). Higher IMR was associated with heart failure 
hospitalizations, death/ heart failure hospitalizations, and 
MACE (Table VII in the Data Supplement).
CFR
In those with CFR≤2.0, heart failure hospitalizations 
occurred in 18 patients (15.7%), death/heart failure 
hospitalization occurred in 20 patients (17.4%) and 
MACE occurred in 21 patients (18.3%). The optimal 
CFR threshold for predicting heart failure hospitaliza-
tion was ≤1.8 (AUC: 0.64 [P=0.019]). The optimal CFR 
Figure 3. DeLong comparisons of receiver operating characteristic curves, showing performance of index of microcirculatory 
resistance (IMR), coronary flow reserve (CFR), and resistive reserve ratio (RRR). 
The predictive ability of IMR, CFR and RRR are shown for the following: (A) microvascular obstruction (MVO) presence/absence; (B) 
myocardial hemorrhage presence/absence; (C) hospitalization for heart failure; and (D) major adverse cardiac events.
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threshold for predicting death/ heart failure hospital-
ization or MACE was ≤1.3 (AUCs: 0.63 [P=0.038] and 
0.61 [P=0.073], respectively; Figure 3). Neither continu-
ous CFR, CFR≤2.0, nor CFR≤1.4 (median) were asso-
ciated with heart failure hospitalizations, death/heart 
failure hospitalization, or MACE (Table VII in the Data 
Supplement).
RRR
In those with RRR≤1.7, heart failure hospitalizations 
occurred in 14 (18.2%) patients, death/heart failure 
hospitalization occurred in 16 (20.8%) patients, and 
MACE occurred in 16 (20.8%) patients. The optimal 
RRR threshold for predicting heart failure hospitaliza-
tion, or death/heart failure hospitalization was ≤1.6 
(AUCs: 0.64 [P=0.016] and 0.62 [P=0.040], respec-
tively). The optimal RRR threshold for predicting MACE 
was ≤2.2 (AUC: 0.59 [P=0.128]; Figure 3). Continuous 
RRR was associated with heart failure hospitalization, 
whereas RRR≤1.7 was not. RRR was not associated 
with death/heart failure hospitalization, or MACE (Table 
VII in the Data Supplement).
CFR and RRR in Combination
The combination of CFR≤2.0 and RRR≤1.7 did not 
enhance the prognostic significance of CFR≤2.0 and 
RRR>1.7 combined for association with heart failure 
hospitalization (14/77 [18.2%] versus 4/38 [10.5%]; 
OR, 1.89 [95% CI, 0.58–6.19]; P=0.294), death/heart 
failure hospitalization (16/77 [20.8] versus 4/38 [10.5]; 
OR, 2.23 [95% CI, 0.69–7.21]; P=0.180), or MACE 
(16/77 [20.8] versus 5/38 [13.2%]; OR, 1.73 [95% CI, 
0.58–5.15]; P=0.324).
DISCUSSION
Our study provides new insights into the comparative clin-
ical significance of invasive measures of microvascular 
function during primary PCI. Although CFR and RRR are 
correlated, we observed discordance between high and 
low dichotomized CFR and RRR values in 38 patients 
(26%), indicating that these parameters have overlap-
ping and distinct behaviours. Furthermore, we observed 
differences in the associations of CFR and RRR, and 
their combination with MVO, myocardial hemorrhage, 
infarct size, and clinical outcomes, implying these tests 
do not have equivalent clinical significance.
IMR and RRR reflect different aspects of microvas-
cular function and are complementary. IMR does not 
reflect microvascular vasodilator capacity. IMR may 
not reflect the full potential for the microcirculation to 
Table 2. Associations of Coronary Physiology and Angiogram Parameters With MVO, or Myocardial Hemorrhage Extent, 
From Linear Regression and Their Associations With MVO, or Myocardial Hemorrhage, Presence From Logistic Regression
Univariable Multivariable Univariable Multivariable
 Association with MVO extent (% LV; n=140) Association with MVO presence (n=140)
Continuous IMR* 0.01 (0.01 to 0.02); P=0.001 0.01 (−0.00 to 0.02); P=0.070 1.01 (1.00 to 1.02); P=0.024 1.01 (0.99 to 1.02); P=0.376
IMR>40* 0.78 (0.36 to 1.20); P<0.001 0.53 (0.05 to 1.02); P=0.031 3.34 (1.64 to 6.80); P=0.001 2.79 (1.14 to 6.81); P=0.025
Continuous CFR† −0.50 (−0.81 to −0.18); P=0.002 −0.12 (−0.60 to 0.37); P=0.631 0.52 (0.29 to 0.93); P=0.028 0.91 (0.34 to 2.38); P=0.839
CFR≤2.0† 0.35 (−0.19 to 0.88); P=0.200 −0.29 (−0.89 to 0.31); P=0.335 1.30 (0.55 to 3.07); P=0.548 0.45 (0.14 to 1.43); P=0.176
Continuous RRR‡ −0.45 (−0.69 to −0.20); P<0.001 −0.60 (−0.97 to −0.23); P=0.002 0.51 (0.31 to 0.83); P=0.007 0.32 (0.14 to 0.73); P=0.007
RRR≤1.7 (median)‡ 0.67 (0.26 to 1.09); P=0.002 0.58 (0.10 to 1.07); P=0.020 2.19 (1.09 to 4.39); P=0.027 2.25 (0.88 to 5.71); P=0.090
TFC post-PCI§ 0.01 (−0.01 to 0.03); P=0.208 −0.01 (−0.02 to 0.01); P=0.520 1.01 (0.99 to 1.04); P=0.389 0.98 (0.95 to 1.01); P=0.203
MPG≤1 post-PCI∥ 0.71 (0.27 to 1.16); P=0.002 0.54 (0.07 to 1.01); P=0.026 4.04 (1.90 to 8.59); P<0.001 3.79 (1.62 to 8.88); P=0.002
 Association with myocardial hemorrhage extent (% LV; n=131) Association with myocardial hemorrhage presence (n=136)
Continuous IMR* 0.01 (0.00 to 0.01); P=0.025 0.01 (−0.00 to 0.01); P=0.185 1.01 (1.00 to 1.02); P=0.090 1.00 (0.99 to 1.02); P=0.699
IMR>40* 0.55 (0.13 to 0.96); P=0.010 0.46 (−0.04 to 0.97); P=0.073 3.27 (1.59 to 6.72); P=0.001 3.20 (1.25 to 8.24); P=0.016
Continuous CFR† −0.40 (−0.70 to −0.10); P=0.010 −0.08 (−0.56 to 0.40); P=0.741 0.52 (0.29 to 0.93); P=0.028 0.95 (0.36 to 2.50); P=0.917
CFR≤2.0† 0.26 (−0.24 to 0.76); P=0.298 −0.27 (−0.86 to 0.32); P=0.360 1.34 (0.56 to 0.32); P=0.511 0.44 (0.14 to 1.42); P=0.169
Continuous RRR‡ −0.36 (−0.59 to −0.12); P=0.003 −0.52 (−0.88 to −0.15); P=0.006 0.51 (0.31 to 0.83); P=0.007 0.34 (0.15 to 0.75); P=0.008
RRR≤1.7 (median)‡ 0.55 (0.15 to 0.95); P=0.007 0.54 (0.05 to 1.02); P=0.030 2.20 (1.09 to 4.44); P=0.028 2.30 (0.90 to 5.87); P=0.081
TFC post-PCI§ 0.01 (−0.01 to 0.02); P=0.490 −0.01 (−0.03 to 0.01); P=0.291 1.01 (0.98 to 1.04); P=0.397 0.97 (0.93 to 1.01); P=0.091
MPG≤1 post-PCI∥ 0.44 (−0.01 to 0.88); P=0.054 0.31 (−0.16 to 0.79); P=0.194 3.72 (1.75 to 7.95); P=0.001 3.41 (1.44 to 8.05); P=0.005
Results are reported as regression coefficient or OR, 95% CI, and P value. MVO and myocardial hemorrhage extent (2–7 d post-PCI) were analyzed on square root 
scales. CFR indicates coronary flow reserve; IMR, index of microcirculatory resistance; LV, left ventricle; MPG, myocardial perfusion grade; MVO, microvascular obstruc-
tion; OR, odds ratio; PCI, percutaneous coronary intervention; RRR, resistive reserve ratio; and TFC, Thrombolysis in Myocardial Infarction frame count.
*Covariates in multivariable analyses for association of IMR with MVO, or myocardial hemorrhage: CFR≤2.0, RRR≤1.7, TFC post-PCI, and MPG≤1 post-PCI.
†Covariates in multivariable analyses for association of CFR with MVO, or myocardial hemorrhage: IMR>40, RRR≤1.7, TFC post-PCI and MPG≤1 post-PCI.
‡Covariates in multivariable analyses for association of RRR with MVO, or myocardial hemorrhage: IMR>40, CFR≤2.0, TFC post-PCI, and MPG≤1 post-PCI.
§Covariates in multivariable analyses for association of TFC post-PCI with MVO, or myocardial hemorrhage: IMR>40, CFR≤2.0, RRR≤1.7, and MPG≤1 post-PCI.
∥Covariates in multivariable analyses for association of MPG≤1 post-PCI with MVO, or myocardial hemorrhage: IMR>40, CFR≤2.0, RRR≤1.7, and TFC post-PCI.
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recover following reperfusion. RRR is a measure of the 
capacity of the coronary microcirculation to change from 
baseline to hyperemia, reflecting the ability to achieve 
maximal hyperemia.14,15 Lower RRR values indicate 
poor vasodilator capacity of the coronary microcircula-
tion. Compared with CFR, RRR may better reflect the 
potential for the microcirculation to recover following 
reperfusion. RRR may provide additional information 
than what is obtained from currently available measures 
of microvascular function (CFR and IMR).
In prior studies, RRR was lower in patients with STEMI 
compared with non-STEMI and stable angina.14 More-
over, RRR measured in nonculprit vessels was lower 
acutely versus 1 month later, indicating a blunted hyper-
emic vasodilatory response acutely.16 In 45 acute STEMI 
patients, RRR≤1.98 (median for the cohort) measured 
post-primary PCI was associated with MVO extent 2 days 
post-PCI and infarct size at 6 months.15 However, to date, 
these findings have not been verified in a larger cohort 
and the association between RRR and clinical outcomes 
is unknown. Our study adds new data by (1) showing that 
RRR is associated with heart failure hospitalizations and 
(2) quantitatively comparing established coronary physi-
ology parameters in both continuous and dichotomized 
form with the amount of MVO and hemorrhage.
Reliable identification of patients with high probability 
of having microvascular damage has potential to iden-
tify those patients in the catheterization laboratory for 
adjunctive therapies and inclusion in therapeutic trials. 
A test with a binary cutoff (normal/abnormal) is gener-
ally helpful for patient stratification. However, the optimal 
threshold may vary between different populations and 
different end points of interest. We chose established 
thresholds when dichotomizing IMR and CFR based 
on prior literature, that is, >40 and ≤2.0, respectively.12 
There is no established threshold for RRR; therefore, 
the median was chosen when dichotomizing RRR. We 
observed discordance between dichotomized IMR>40 
and MVO presence in just over one-third of patients 
(40%), which is similar to prior literature.8 Discordance 
was relatively higher between RRR≤1.7 and MVO pres-
ence (51%) and between CFR≤2.0 and MVO presence 
(58%). There are 2 explanations to consider. First, the 
extent of MVO varies in patients who have MVO pres-
ent. Higher IMR and lower RRR or CFR are correlated 
with greater amounts of MVO, hence one would expect 
there to be discordance when binary thresholds are 
applied. Second, microvascular dysfunction is dynamic 
within minutes to the first few days post-reperfusion. 
When microvascular function is measured immediately 
post-primary PCI, reversible edema may contribute more 
to microvascular dysfunction, than on CMR 2 to 7 days 
later, where irreversible microvascular injury (including 
extravasation of red blood cells) may persist.
IMR>40 is being used to select patients for inclusion 
in clinical trials of adjunctive therapy during primary PCI, 
for example, pressure-controlled intermittent coronary 
sinus occlusion.3,21 Our study suggests that RRR may 
have potential as a superior tool compared with CFR, to 
guide patient selection for adjunctive therapy.
Although MPG≤1 post-PCI (but not TFC) was mul-
tivariably associated with more MVO, myocardial hem-
orrhage presence, and infarct size, and both MPG≤1, 
and TFC were associated with clinical outcomes, these 
parameters have several drawbacks. In particular, MPG 
is not quantitative, and the visual assessment of MPG 
has limited reproducibility.22 TFC provides a quantitative 
assessment of coronary blood flow, but it is confounded 
by nitrate use, heart rate, and the phase of the cardiac 
cycle in which dye is injected.23
Table 3. Associations of Coronary Physiology and Angiogram Parameters With Infarct Size, 3 Months 
Post-PCI, From Linear Regression
Association With Infarct Size (% LV; n=133)
Univariable Multivariable
Continuous IMR* 0.12 (0.07 to 0.18); P<0.001 0.05 (−0.02 to 0.11); P=0.157
IMR>40* 9.12 (5.40 to 12.84); P<0.001 5.05 (0.84 to 9.26); P=0.019
Continuous CFR† −3.91 (−6.87 to −0.95); P=0.010 −0.61 (−4.87 to 3.66); P=0.779
CFR≤2.0† 3.56 (−1.38 to 8.51); P=0.157 −1.51 (−6.73 to 3.71); P=0.567
Continuous RRR‡ −3.74 (−6.13 to −1.34); P=0.002 −3.41 (−6.76 to −0.06); P=0.046
RRR≤1.7 (median)‡ 5.26 (1.40 to 9.13); P=0.008 3.25 (−1.00 to 7.50); P=0.133
TFC post-PCI§ 0.30 (0.16 to 0.44); P<0.001 0.13 (−0.02 to 0.28); P=0.091
MPG≤1 post-PCI∥ 9.29 (5.38 to 13.20); P<0.001 5.87 (1.75 to 10.00); P=0.006
Results are reported as regression coefficient, with 95% CI and P value. CFR indicates coronary flow reserve; IMR, index of microcircula-
tory resistance; LV, left ventricle; MPG, myocardial perfusion grade; PCI, percutaneous coronary intervention; RRR, resistive reserve ratio; and 
TFC, Thrombolysis in Myocardial Infarction frame count.
*Covariates in multivariable analyses for association of IMR with infarct size: CFR≤2.0, RRR≤1.7, TFC post-PCI, and MPG≤1 post-PCI.
†Covariates in multivariable analyses for association of CFR with infarct size: IMR>40, RRR≤1.7, TFC post-PCI, and MPG≤1 post-PCI.
‡Covariates in multivariable analyses for association of RRR with infarct size: IMR>40, CFR≤2.0, TFC post-PCI, and MPG≤1 post-PCI.
§ Covariates in multivariable analyses for association of TFC post-PCI with infarct size: IMR>40, CFR≤2.0, RRR≤1.7 and MPG≤1 post-PCI.
∥Covariates in multivariable analyses for association of MPG≤1 post-PCI infarct size: IMR>40, CFR≤2.0, RRR≤1.7, and TFC post-PCI.
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Limitations and Strengths
Strengths of our study include (1) multicenter enrolment, 
increasing generalizability, (2) blinding of coronary physi-
ology measurements to minimize bias, (3) independent 
adjudication of clinical events, and (4) CMR was avail-
able in almost all patients (97%) at 2 to 7 days.
Limitations include the relatively small number of 
clinical events, which limited power to detect statistically 
significant associations. Since these were all emergency 
patients, they would not have withheld from caffeine, 
which could have affected response to adenosine and 
thus maximal hyperemia could not be guaranteed in all 
patients. However, these limitations apply to the previ-
ously published coronary physiology studies in the con-
text of acute STEMI.5,7,8,12
Patients were not enrolled consecutively. Out of the 
440 patients in the T-TIME trial, 284 patients had no 
invasive coronary physiology performed, and 7 patients 
had failed attempts at coronary physiology measure-
ments (Figure 1). Typically, STEMI studies include a 
majority of left anterior descending artery infarcts. The 
reason for why invasive coronary physiology was most 
frequently performed in right coronary arteries is unclear, 
but one explanation may be logistical pressures for cath-
eterization laboratory access given that it is typically eas-
ier to pass wires in the right coronary arteries than the 
left anterior descending.
Conclusions
In patients with acute STEMI presenting within 6 
hours of symptom onset, RRR and IMR were associ-
ated with MVO extent, myocardial hemorrhage pres-
ence, infarct size and clinical outcomes, whereas CFR 
was not. Compared with CFR, RRR seems to have 
superior potential for stratified therapy. More research 
is warranted.
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